Adverse events at 3 to 12 months' · eyes with acute endophthalmitis following an intraocular procedure (e.g. surgery, intravitreous injection)
Combined steroid and antibiotic therapy showed no clear difference in adverse events at 3 to 12 months' compared with antibiotics alone (low certainty).
1 finding from 1 review
Costs · eyes with acute endophthalmitis following an intraocular procedure (e.g. surgery, intravitreous injection)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · people hospitalised with COVID‐19
Higher‐dose anticoagulants showed no clear difference in all‐cause mortality compared with lower‐dose anticoagulants (high certainty).
1 finding from 1 review
Necessity for additional respiratory support · people hospitalised with COVID‐19
It is very uncertain whether higher‐dose anticoagulants changes necessity for additional respiratory support compared with lower‐dose anticoagulants (very low certainty).
1 finding from 1 review
Mortality related to COVID‐19 · people hospitalised with COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Deep vein thrombosis · people hospitalised with COVID‐19
Higher‐dose anticoagulants showed no clear difference in deep vein thrombosis compared with lower‐dose anticoagulants (low certainty).
1 finding from 1 review
Pulmonary embolism · people hospitalised with COVID‐19
Higher‐dose anticoagulants probably leads to lower pulmonary embolism compared with lower‐dose anticoagulants (moderate certainty).
1 finding from 1 review
Major bleeding · people hospitalised with COVID‐19
Higher‐dose anticoagulants probably leads to higher major bleeding compared with lower‐dose anticoagulants (moderate certainty).
1 finding from 1 review
Adverse events (minor bleeding) · people hospitalised with COVID‐19
Higher‐dose anticoagulants leads to higher adverse events (minor bleeding) compared with lower‐dose anticoagulants (high certainty).
1 finding from 1 review
Psychophysical testing for recovery of sense of smell · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection
It is very uncertain whether systemic corticosteroids plus intranasal… changes psychophysical testing for recovery of sense of smell compared with no intervention (very low certainty).
1 finding from 1 review
Serious adverse events · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection
1 finding from 1 review
Change in sense of smell · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection
1 finding from 1 review
Generic quality of life measures · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Presence of parosmia · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Other adverse outcomes · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection
1 finding from 1 review
Disease‐related quality of life · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection
1 finding from 1 review
Change in sense of smell · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection
1 finding from 1 review
Generic quality of life measures · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Presence of parosmia · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found